Evidence map›Paper›PMID 37265478›Full record

ArticleApplied physics reviews2023

A point-of-care biosensor for rapid detection and differentiation of COVID-19 virus (SARS-CoV-2) and influenza virus using subwavelength grating micro-ring resonator.

Shupeng Ning, Hao-Chen Chang, Kang-Chieh Fan, Po-Yu Hsiao, Chenghao Feng, Devan Shoemaker, Ray T Chen

Open access · greenAbstract read
In one paragraph

Article in Applied physics reviews, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Shupeng NingDepartment of Electrical and Computer Engineering, The University of Texas at Austin, Austin, Texas 78758, USA.ORCID https://orcid.org/0000-0002-5780-9711
Hao-Chen ChangOmega Optics, Inc., 8500 Shoal Creek Blvd., Austin, Texas 78757, USA.
Kang-Chieh FanDepartment of Electrical and Computer Engineering, The University of Texas at Austin, Austin, Texas 78758, USA.
Po-Yu HsiaoDepartment of Electrical and Computer Engineering, The University of Texas at Austin, Austin, Texas 78758, USA.ORCID https://orcid.org/0009-0009-6172-1454
Chenghao FengDepartment of Electrical and Computer Engineering, The University of Texas at Austin, Austin, Texas 78758, USA.ORCID https://orcid.org/0000-0002-0751-7681
Devan ShoemakerDepartment of Electrical and Computer Engineering, The University of Texas at Austin, Austin, Texas 78758, USA.ORCID https://orcid.org/0009-0008-0917-103X
The University of Texas at Austin · USOmega Optics (United States) · US

Funding

NCI NIH HHS HHSN261201200043C
6 · The paper itself

Abstract

In the context of continued spread of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 and the emergence of new variants, the demand for rapid, accurate, and frequent detection is increasing. Moreover, the new predominant strain, Omicron variant, manifests more similar clinical features to those of other common respiratory infections. The concurrent detection of multiple potential pathogens helps distinguish SARS-CoV-2 infection from other diseases with overlapping symptoms, which is significant for providing tailored treatment to patients and containing the outbreak. Here, we report a lab-on-a-chip biosensing platform for SARS-CoV-2 detection based on the subwavelength grating micro-ring resonator. The sensing surface is functionalized by specific antibody against SARS-CoV-2 spike protein, which could produce redshifts of resonant peaks by antigen-antibody combination, thus achieving quantitative detection. Additionally, the sensor chip is integrated with a microfluidic chip featuring an anti-backflow Y-shaped structure that enables the concurrent detection of two analytes. In this study, we realized the detection and differentiation of COVID-19 and influenza A H1N1. Experimental results indicate that the limit of detection of our device reaches 100 fg/ml (1.31 fM) within 15 min detecting time, and cross-reactivity tests manifest the specificity of the optical diagnostic assay. Furthermore, the integrated packaging and streamlined workflow facilitate its use for clinical applications. Thus, the biosensing platform presents a promising approach for attaining highly sensitive, selective, multiplexed, and quantitative point-of-care diagnosis and distinction between COVID-19 and influenza.

Identifiers

PMID37265478
PMCPMC10228026
OpenAlexW4378215278

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.